Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Nuvation Bio, a late clinical-stage biopharmaceutical company focused on oncology, announced that its CEO, David Hung, M.D., will present at the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 1:30 p.m. ET. A live webcast of the presentation will be available on the Nuvation Bio website, with an archived recording accessible for 90 days.

Positive

• Nuvation Bio's participation in a high-profile conference like Jefferies Global Healthcare Conference can increase its visibility among investors and industry experts.
• A live webcast and archived recording make the information accessible, potentially enhancing investor engagement.

Negative

• The announcement lacks specific updates on clinical trials or financial performance, which could leave investors wanting more substantial information.
• Relying on conference presentations for visibility may not be sufficient to drive significant investor interest without accompanying strong, tangible results.

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a hybrid presentation at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 5, 2024, at 1:30 p.m. ET.

A live webcast of the hybrid presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.

About Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529318170/en/

Nuvation Bio Investor Contact:

ir@nuvationbio.com

Nuvation Bio Media Contact:

nuvation@argotpartners.com

Source: Nuvation Bio Inc.

FAQ

When will Nuvation Bio present at the Jefferies Global Healthcare Conference?

Nuvation Bio will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 1:30 p.m. ET.

Who will represent Nuvation Bio at the Jefferies Global Healthcare Conference?

David Hung, M.D., Founder, President, and CEO of Nuvation Bio, will present at the conference.

How can I watch Nuvation Bio's presentation at the Jefferies Global Healthcare Conference?

A live webcast of Nuvation Bio's presentation will be available on the Nuvation Bio website, and an archived recording will be accessible for 90 days.

What is the stock symbol for Nuvation Bio?

The stock symbol for Nuvation Bio is NUVB.